Among all patients with CRC who had a loss of MLH1/PMS2 with BRAF V600E or MLH1 promoter hypermethylation, 2 of 16 were ultimately found to have a pathogenic germline mutation, but neither of these patients had Lynch syndrome, with one having an increased risk allele for prostate cancer. This evidence concerns the gene PMS2 and Familial prostate cancer.